ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
Phase 2a proof-of concept clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease (DKD) ...
Marius Pharmaceuticals Strengthens IP Portfolio with New KYZATREX® (testosterone undecanoate) CIII Capsules Formulation Patent
This marks Marius Pharmaceuticals’ fifth U.S. patent, further reinforcing its leadership in the field of testosterone replacement therapy. The newly allowed patent specifically covers the company’s ...